An upsized $317.5 million offering gives Lycia Therapeutics (NASDAQ: LYCA) fresh capital to pursue protein-degrading medicines, with early human data and 2027 clinical milestones sharpening the investment story.
October 24, 2026
Wall Street has found a biotechnology company with an unusually literal…